Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tramadol ANDAs are “approvable”

Executive Summary

Teva, Apotex and Watson generics of J&J's Ultram (tramadol) are "approvable" at FDA while the agency resolves whether patent-protected sections of Ultram labeling are essential for safety and efficacy of the pain relief agent. In a November citizen petition, Apotex argued that the titration dosing schedules added to labeling were not prompted by safety or efficacy concerns (1"The Pink Sheet" Nov. 19, 2001, p. 14). Par also has an ANDA pending...

You may also be interested in...

J&J Ultram Titration Relabeling Should Not Block Generics, Apotex Argues

Apotex' citizen petition requesting approval of generic Ultram argues that Johnson & Johnson did not make labeling changes for safety or efficacy reasons

Sandoz Looks Ahead To Biosimilar Opportunities

Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.

UK/EU Industry ‘Still Working In The Dark’ On Post-Brexit Regulation

As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts